US regional and demographic differences in prescription opioid and heroin-related overdose hospitalizations

International Journal of Drug Policy

Volumn 46, Issue , 2017, Pages 112-119

  Unick, George Jay ^a   Ciccarone, Daniel ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fentanyl Overdose; Heroin Overdose; Prescription Opioid Overdose

Indexed keywords

DIAMORPHINE; NARCOTIC ANALGESIC AGENT; FENTANYL;

AGE; ARTICLE; COMPARATIVE STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG INTOXICATION; DRUG OVERDOSE; EPIDEMIC; ETHNIC DIFFERENCE; GEOGRAPHIC DISTRIBUTION; HELP SEEKING BEHAVIOR; HOSPITALIZATION; HUMAN; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; TREND STUDY; UNITED STATES; ADULT; FEMALE; HEROIN DEPENDENCE; MALE; MIDDLE AGED; OPIATE ADDICTION; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; ANALGESICS, OPIOID; DRUG OVERDOSE; FEMALE; FENTANYL; HEROIN; HEROIN DEPENDENCE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; UNITED STATES; YOUNG ADULT;

EID: 85021802717     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2017.06.003     Document Type: Article

References (33)

1. Banerjee, G., Edelman, E.J., Barry, D.T., Becker, W.C., Cerda, M., Crystal, S., Marshall, B.D., Non-medical use of prescription opioids is associated with heroin initiation among US veterans: A prospective cohort study. Addiction 111:11 (2016), 2021–2031, 10.1111/add.13491.
2. Cerda, M., Santaella, J., Marshall, B.D., Kim, J.H., Martins, S.S., Nonmedical prescription opioid use in childhood and early adolescence predicts transitions to heroin use in young adulthood: A national study. Journal of Pediatrics 167:3 (2015), 605–612, 10.1016/j.jpeds.2015.04.071 e601-602.
3. Ciccarone, D., With both eyes open: Notes on a disciplinary dialogue between ethnographic and epidemiological research among injection drug users. International Journal of Drug Policy 14:1 (2003), 115–118.
4. Ciccarone, D., Editorial: Fentanyl in the US heroin supply: a rapidly changing risk environment. International Journal of Drug Policy 46 (2017), 107–111.
5. Ciccarone, D., Mars, S., Ondocsin, J., Heroin uncertainties: Exploring users’ perceptions of fentanyl-adulterated and-substituted ‘heroin’. International Journal of Drug Policy 46 (2017), 146–155.
6. Cicero, T.J., Ellis, M.S., Harney, J., Shifting patterns of prescription opioid and heroin abuse in the United States. The New England Journal of Medicine 373:18 (2015), 1789–1790, 10.1056/NEJMc1505541.
7. Cicero, T.J., Ellis, M.S., Surratt, H.L., Kurtz, S.P., The changing face of heroin use in the United States: Aretrospective analysis of the past 50 years. JAMA Psychiatry 71:7 (2014), 821–826, 10.1001/jamapsychiatry.2014.366.
8. Compton, W.M., Jones, C.M., Baldwin, G.T., Relationship between nonmedical prescription-opioid use and heroin use. The New England Journal of Medicine 374:2 (2016), 154–163, 10.1056/NEJMra1508490.
9. Dart, R.C., Surratt, H.L., Cicero, T.J., Parrino, M.W., Severtson, S.G., Bucher-Bartelson, B., Green, J.L., Trends in opioid analgesic abuse and mortality in the United States. The New England Journal of Medicine 372:3 (2015), 241–248, 10.1056/NEJMsa1406143.
10. Frank, R.G., Pollack, H.A., Addressing the fentanyl threat to public health. The New England Journal of Medicine 376:7 (2017), 605–607, 10.1056/NEJMp1615145.
11. Frenk, S.M., Porter, K.S., Paulozzi, L.J., Prescription opioid analgesic use among adults: United States, 1999–2012. NCHS Data Brief 189 (2015), 1–8.
12. Gladden, R.M., Martinez, P., Seth, P., Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths—27 States, 2013–2014. The Morbidity and Mortality Weekly Report (MMWR) 65:33 (2016), 837–843, 10.15585/mmwr.mm6533a2.
13. Goldsamt, L.A., Harocopos, A., Kobrak, P., Jost, J.J., Clatts, M.C., Circumstances, pedagogy and rationales for injection initiation among new drug injectors. The Journal of Community Health 35:3 (2010), 258–267, 10.1007/s10900-010-9231-z.
14. Grau, L.E., Dasgupta, N., Harvey, A.P., Irwin, K., Givens, A., Kinzly, M.L., Heimer, R., Illicit use of opioids: Is OxyContin a “gateway drug”?. The American Journal on Addictions 16:3 (2007), 166–173, 10.1080/10550490701375293.
15. Healthcare Cost and Utilization Project (HCUP), Trend HCUP NIS trend weights. 2015 Retrieved from www.hcup-us.ahrq.gov/db/nation/nis/trendwghts.jsp.
16. Hedegaard, H., Warner, M., Minino, A.M., Drug overdose deaths in the United States, 1999–2015. NCHS Data Brief 273 (2017), 1–8.
17. Houchens, R., Ross, D., Elixhauser, A., Jiang, J., Nationwide inpatient sample (NIS) redesign final report., 2014 Retrieved from http://www.hcup-us.ahrq.gov/reports/methods/methods.jsp.
18. Jones, C.M., Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers—United States, 2002–2004 and 2008–2010. Drug and Alcohol Dependence 132:1–2 (2013), 95–100, 10.1016/j.drugalcdep.2013.01.007.
19. Jones, C.M., Logan, J., Gladden, R.M., Bohm, M.K., Vital signs: Demographic and substance use trends among heroin users—United States, 2002–2013. The Morbidity and Mortality Weekly Report (MMWR) 64:26 (2015), 719–725.
20. Kleinig, J., Ready for retirement: The gateway drug hypothesis. Substance Use & Misuse 50:8–9 (2015), 971–975, 10.3109/10826084.2015.1007679.
21. Lucyk, S.N., Nelson, L.S., Novel synthetic opioids: An opioid epidemic within an opioid epidemic. Annals of Emergency Medicine 69:1 (2017), 91–93, 10.1016/j.annemergmed.2016.08.445.
22. Mars, S., Bourgois, P., Karandinos, G., Montero, F., Ciccarone, D., “Every ‘never’ I ever said came true”: Transitions from opioid pills to heroin injecting. International Journal of Drug Policy 25:2 (2014), 257–266, 10.1016/j.drugpo.2013.10.004.
23. Martins, S.S., Sarvet, A., Santaella-Tenorio, J., Changes in US lifetime heroin use and heroin use disorder. JAMA Psychiatry 74:4 (2017), 445–455, 10.1001/jamapsychiatry.2017.0113.
24. Potier, C., Laprévote, V., Dubois-Arber, F., Cottencin, O., Rolland, B., Supervised injection services: What has been demonstrated? A systematic literature review. Drug and Alcohol Dependence 145 (2014), 48–68.
25. Reardon, J.M., Harmon, K.J., Schult, G.C., Staton, C.A., Waller, A.E., Use of diagnosis codes for detection of clinically significant opioid poisoning in the emergency department: A retrospective analysis of a surveillance case definition. BMC Emergency Medicine, 16, 2016, 11, 10.1186/s12873-016-0075-4.
26. Rudd, R.A., Seth, P., David, F., Scholl, L., Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. The Morbidity and Mortality Weekly Report (MMWR) 65:5051 (2016), 1445–1452, 10.15585/mmwr.mm655051e1.
27. SAS Institute Inc, SAS/ACCESS 9.4 interface to ADABAS: Reference. 2013, SAS Institute Inc., Cary, NC.
28. Slavova, S., Bunn, T.L., Talbert, J., Drug overdose surveillance using hospital discharge data. Public Health Reports 129:5 (2014), 437–445, 10.1177/003335491412900507.
29. Somerville, N.J., O'Donnell, J., Gladden, R.M., Zibbell, J.E., Green, T.C., Younkin, M.,.. Walley, A.Y., Characteristics of fentanyl overdose—Massachusetts, 2014–2016. The Morbidity and Mortality Weekly Report (MMWR) 66:14 (2017), 382–386, 10.15585/mmwr.mm6614a2.
30. StataCorp, Stata Statistical Software: Release 14. 2015, StataCorp LP.
31. U.S. Drug Enforcement Administration Diversion Control Division, NFLIS brief: Fentanyl, 2001–2005. 2017, Springfield, VA.
32. Unick, G., Rosenblum, D., Mars, S., Ciccarone, D., The relationship between US heroin market dynamics and heroin-related overdose, 1992–2008. Addiction 109:11 (2014), 1889–1898, 10.1111/add.12664.
33. Unick, G.J., Rosenblum, D., Mars, S., Ciccarone, D., Intertwined epidemics: National demographic trends in hospitalizations for heroin- and opioid-related overdoses, 1993–2009. PLoS One, 8(2), 2013, e54496, 10.1371/journal.pone.0054496.